vTv Therapeutics (VTVT) Non-Current Assets (2014 - 2026)
vTv Therapeutics (VTVT) posted Non-Current Assets of $5000.0 for Q1 2026, down 16.67% sequentially from $6000.0 in Q4 2025, and down 95.5% YoY from $111000.0 in Q1 2025.
vTv Therapeutics (VTVT) Non-Current Assets (2014 - 2026) Analysis & Trends
vTv Therapeutics has reported Non-Current Assets for 13 years, with the latest figure at $5000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 95.5% year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $123000.0 (down 83.1% YoY) and the FY2025 annual result came in at $6000.0, down 96.08% from the prior year.
- Non-Current Assets eased to $5000.0 in Q1 2026 per VTVT's latest filing, from $6000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $8.5 million in Q2 2023 and troughed at $5000.0 in Q1 2026.
- A 5-year average of $2.9 million and a median of $311000.0 in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets soared 33.04% in 2023, then plunged 96.96% in 2024.
- Over 5 years, Non-Current Assets stood at $6.1 million in 2022, then plunged by 94.12% to $361000.0 in 2023, then plunged by 57.62% to $153000.0 in 2024, then tumbled by 96.08% to $6000.0 in 2025, then fell by 16.67% to $5000.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $5000.0, $6000.0, and $38000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | vTv Therapeutics | 373.77 Mn | 373.77 Mn | - | 4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 38,000.00 |
| Jun 30, 2025 | 74,000.00 |
| Mar 31, 2025 | 111,000.00 |
| Dec 31, 2024 | 153,000.00 |
| Sep 30, 2024 | 206,000.00 |
| Jun 30, 2024 | 258,000.00 |
| Mar 31, 2024 | 311,000.00 |
| Dec 31, 2023 | 361,000.00 |
| Sep 30, 2023 | 4.80 Mn |
| Jun 30, 2023 | 8.49 Mn |
| Mar 31, 2023 | 8.20 Mn |
| Dec 31, 2022 | 6.14 Mn |
| Sep 30, 2022 | 6.73 Mn |
| Jun 30, 2022 | 6.38 Mn |
| Mar 31, 2022 | 6.57 Mn |
| Dec 31, 2021 | 9.85 Mn |
| Sep 30, 2021 | 9.26 Mn |